Outlook Therapeutics found using ticker (OTLK) now have 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 8 and 3.25 calculating the mean target price we have 5.25. Now with the previous closing price of 1.47 this would imply there is a potential upside of 257.1%. The 50 day MA is 1.15 while the 200 day moving average is 1.08. The company has a market cap of $195m. Company Website: http://www.outlooktherapeutics.com
Outlook Therapeutics, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics and changed its name to Outlook Therapeutics in November 2018. Outlook Therapeutics was founded in 2010 and is headquartered in Cranbury, New Jersey.